Oct 28

Buried at the end of the last post — on the GQ magazine story related to Personalized Health — was a jewel of a link to a quick, four-minute streaming video from the Interleukin Genetics site. It’s simply titled, The Science Behind Interleukin Genetics

If you’ve ever pondered over how to explain to a retail customer (or a potential business associate) what the Gensona DNA tests are about and the life-long value of the information they provide, now you don’t (have to ponder). Just refer your retail customer or potential business associate to this link for a quick, easy-to-understand presentation.

The Science Behind Interleukin Genetics

****************

Still with me? Attention span longer than you  thought? (hehe) 

Beyond that, you should still know something about the Nutrilite brand and why it gives us such a unique position in the marketplace. If you don’t know how to talk about Nutrilite’s history and the just-in-time fresh fresh freshness of the organic functional-whole-food-based products you represent, here are a few more “movies” to which you can go (and take your retail customer along).

Washington State organic farm

Mexico organic farm

Brazil organic farm

Optimal Health: The Heart of the Original Brand

Lifestyle

Personalization

Nutrigenomics

Nutrilite clinical validation studies

Nutrilite research associations

SPEAKING OF AMWAY, don’t foget to watch this space for a timely and provocative three-part series coming very soon from the pen keyboard of Chuck Lia.

Blessings for a great day… :)

written by rdknyvr \\ tags: , , , , , , , , , ,

Oct 24

NOTE TO READERS: text below in bold and blue is hotlinked to additional background info.  

This new article in GQ Magazine, The Book of Me, is of keen interest in that it demonstrates how personal genomics and Personalized Health are now growing in mass market interest in general media outlets, and not just science-oriented journalism and publications.Someone in the Alticor organization had the exceptional foresight back around 2002 or 2003 to recommend an ‘angel investment’ in Interleukin Genetics, which had made some key discoveries — pre-Human Genome Project completion — which are turning out to be core to understanding how our personal genetics influences the ageing process and chronic health conditions related thereto. Interleukin was able to apply for a number of patents based on their unique discoveries and thus claim some significant IP real estate in the “land rush” around human genome research which is shaping the future of health and health care. Alticor has thus far shown good patience with their investment in Interleukin and has provided its Distributors with an unparalleled product and business development opportunity with the Gensona DNA tests, and Nutrilite’s IL-1 Heart Health supplement — the world’s first clinically validated (published in peer-reviewed and respected scientific journals) nutrigenomic supplement – with more in the Nutrilite and Interleukin research pipelines. The article in GQ is an easy read and well-written, almost in a mystery novel genre by a top-selling novelist, so your time spent reading will be enjoyable for those who don’t think they “like” science related stuff, and a joy for those of us who see the future now and can’t wait.A key quote from the article — key for me, at least: 

He [George Church, Harvard University] defends the coming revolution, comparing it to the birth of personal computing in the late 1970s. That earlier revolution was all about mass empowerment, going, he says, “from a few people in the priesthood that guarded the mainframes, to everybody.” But few people saw the potential of that revolution early on: “Just like with personal computing, until there are some compelling stories involving real products [my emphasis] the only people who are going to get what’s happening are the ones who can imagine things that aren’t yet there.”                                        

 SPEAKING OF AMWAY GLOBAL, where do you rank Personalized Health and Nutrilite Health in your list of business development priorities? Is it “hot” or is it “not” for you, and why? Second, what is Amway Global doing well to assist you in understanding and marketing the Gensona DNA tests and the Nutrilite IL-1 Heart Health, and what in your view might they do better?  Before you answer that last question, watch this video clip

written by rdknyvr \\ tags: , , , , , , , , , , , , , , , , , , ,

Sep 12

For those of us focusing on the Personalized Health opportunity, the following excerpt from a press release this morning definitely adds a spring to our step (see quoted section below).

 With Personalized Health — which includes Interleukin Genetics’s patent protected IP and DNA tests, which we market under the Gensona brand, and the IL-1 Heart Health supplement patented by Nutrilitewe truly have an opportunity to reshape the health care debate in North America, even more so than the politicians campaigning for election at this moment in both the US and Canada.

As of next year, 2009, that same Personalized Health opportunity will be available to our colleagues in Asia as well, when Gensona DNA tests are rolled out for markets there.

Paper Reports Value of Specific Nutritional Products is Dependent on Individual’s Genetic Make-up WALTHAM, Mass., Sept. 12

WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ — Researchers at
Interleukin Genetics, Inc. (Amex: ILI), today received the 12th John M. Kinney Award for Nutrition and Metabolism at the annual Congress of the European Society of Parenteral and Enteral Nutrition, in Florence, Italy. The award was given for the paper, “Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept,” which was published in Nutrition: The International Journal of Applied and Basic Nutritional Sciences (2007;23:844-852).

Kenneth Kornman, Ph.D., Chief Scientific Officer at Interleukin Genetics, and the first author on the publication, commented, “We are honored to receive the 12th

John M. Kinney Award for Nutrition and Metabolism. Many botanical and nutritional supplements claim to provide countless health benefits without being subjected to rigorous clinical study. Our paper reports a well- controlled clinical study has shown the value of specific nutritional products is dependent on an individual’s genetic make-up.” The study, a joint research effort by scientists at Interleukin Genetics and Nutrilite, a division of Alticor Inc., is one of the few controlled clinical trials that has shown the value of specific nutritional products is dependent on an individual’s genetic make-up. The data showed that a proprietary botanical supplement (Nutrilite IL1 Heart Health Supplement) could lower inflammation in individuals who tested positive for pro-inflammatory IL-1 gene variations from Interleukin Genetics’ Heart Health Genetic Test. These individuals also had elevated levels of C-reactive protein.

About Interleukin Genetics’ Heart Health Genetic Test

Interleukin Genetics’ Heart Health Genetic Test was developed to identify healthy individuals who are genetically predisposed to over-produce inflammation and are at an increased risk for an early first heart attack.

The Heart Health Genetic Test is marketed on a non-exclusive basis [edit: it became non-exclusive for us only as of last week] through Access Business Group International LLC, a division of Alticor Inc. Interleukin Genetics recently announced an agreement with Access Business Group International that will permit the expansion of Interleukin Genetics’ distribution network for such genetic tests.

About Nutrilite IL1 Heart Health Supplement

Nutrilite IL1 Heart Health Supplement, a proprietary botanical supplement, was developed to reduce inflammation in those individuals who are genetic over-producers. The Nutrilite IL1 Heart Health Supplement is currently marketed by Quixtar, Inc., a division of Alticor Inc.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals(R), which are sold at the nation’s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment.

Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit
www.ilgenetics.com.

Note, of course, that as of last week, Amway Global business owners no longer have the exclusive distribution rights to the Interleukin DNA test IP. Why? Two basic reasons:

(1) Because of Quixtar’ screwed up launch and lack of support for  the Personalized Health product portfolio and health solution two-plus years ago and ongoing. They admitted as much when management acknowledged last year that Personalized Health was the victim of a “launch and abandon” product support mentality that prevailed before Steve Liebeman came on board and took control.

(2) In the old (and growth-destroying) business model — still ‘de facto’ business practice for most – based on the “Systems”-developed and promoted ”buy from yourself and teach others to do the same,” a major product/solution portfolio like Personalized Health was doomed to fail on that count as well. This could just as well be characterized as a “lack of leadership” by organizations which claim to be devoted to teaching leadership principles.

The defining advantage Independent Business Owners still have with Personalized Health is the core “value-add proposition” which we bring to the table — the ability to educate the consumer in a field which requires consumer education to be successful. Under the new retail sales focused paradigm being driven, thankfully, by Steve Lieberman and his new team, Personalized Health finally has an opportunity to flourish, and be the breakout health solution which will take Amway Global in North America way beyond the goals set by Doug DeVos and Steve Van Andel.

 I’m driving down to Portland later today to the Spotlight showcase, and hopefully Personalized Health and Amway Wellness will be getting the “showcase profile” they deserve. With Interleukin Genetics now winning these kinds of international awards for their ground-breaking research, we expect to see Personalized Health being promoted and celebrated front and center.

written by rdknyvr \\ tags: , , , , , , , , , , , , , , , , , , , , , ,

Aug 05

 One more quick post before Chuck puts up the thought provoker he’s been working on!!!

Note that blue text contains a fascinating URL link which you should click on for background info; red text is for emphasis/highlight only.

I’ve recently come across a series of insightful articles about the growth potential for Online Health, and recommend you too check out Sramana Mitra’s excellent blog, Sramana Mitra On Strategy, specifically the 5 article series Web 3.0 and Online Health.

One of the reasons Sramana’s analysis is so important relates to our Online Personalized Health Questionnaire.  This to me is the KEY VALUE ADD piece to the whole Personalized Health value proposition… and critical to supporting sales of the Interleukin Genetics Gensona DNA tests and Nutrilite’s consumable supplements such as Double X and the IL-1 Heart Health Nutrigenomic supplement, and so on.

The online Personalized Health Questionnaire is confidential, it’s free, and via the recommendations made based on the Gensona tests and the lifestyle and health question modules, provides the critical link between the DNA tests, and the appropriate Nutrilite products and lifestyle and diet and behaviour modification recommendations.

The other critical differentiator for Personalized Health in the online health channel/business space, which we have and no one else does, is our direct sales business model with its emphasis on education of the consumer and each business person building a base of retail customers.

And that is why Alticor’s Transformation process is precisely what is needed in order for the company and us to surge over the next couple of years.

But the Personalized Health Questionnaire and our direct sales business model ARE the key differentiators for success against all potential competitors, including ‘23andme‘, Navigenics, DeCodeMe, and a host of other startups and wanna-be’s.

By the way, if you enjoy Sramana’s writing style as much as I do, here’s another wonderful series she has written on the “modernization” of Indian architechureAs India Builds. Her whole series on India will be of interest to any readers from India or desi backgrounds, or any who are as fascinated with that country of contrasts as I am.

Enjoy!

written by rdknyvr \\ tags: , , , , , , , , , , , , , , , , , ,

Aug 05

Note that blue text contains a fascinating URL link which you should click on for background info; red text is for emphasis/highlight only.

This interview on Personal Genetics with Harvard’s George Church (with previous posting reference here), Dr. Dean Ornish, chair of Google Health’s advisory committee, and Dr. David Agus, a leading oncologist and expert in genomic medicine was done on the same day as Charlie Rose’s already posted chat with Dr. Francis Collins.

The level of discussion does not require you to have expertise, and it will help bring everyone a bit more up-to-speed in the fast-emerging field of prevention and personal genetics.

Note that much of what is discussed — especially the discussions around prevention — are very relevant to our business space — Personalized Health – including Gensona DNA tests from Interleukin Genetics, nutrigenomic supplements from Nutrilite, and Amway Wellness.

written by rdknyvr \\ tags: , , , , , , , , , , , ,

Jul 22

Tantalizing hints about new Transformation changes have been leaking out from Alticor sources to bloggers over at Amway Talk (http://www.amwaytalk.com/) — see post on “Transformation: Major Changes Coming in September.” In addition, some have noted the registration by Alticor or its consultants of the domains Amway Wellness.com and Amway Beauty.com.

Now this morning (July 22) comes the press release below: 

WALTHAM, Mass., July 22 /PRNewswire-FirstCall/ — Interleukin Genetics, Inc. (Amex: ILI), today announced the launch of an enhanced test report format and information package for the company’s Heart Health Genetic Test. The test is currently marketed under the brand name Gensona(R) Heart Health Genetic Test by Quixtar/Amway. The new report will include quantified risk information on heart attack and coronary artery disease generated from clinical studies and conducted by the company. The company believes that this enhanced report format will provide individuals and their physicians more complete information about a person’s inflammation-based genetic risk factor for a heart attack. The new package also provides information on the science behind the genetic test and information to help people understand preventive measures and actions that can be taken to lower the risk of heart disease.

In addition, the company will conduct scientific lectures on the Gensona(R) test for interested Quixtar/Amway individual business owners at their scheduled conferences. The first of these lectures will be on Saturday morning and afternoon, July 26, 2008 at the Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel & Convention Center in Valley Forge, PA. Thousands of attendees are expected at the conference.

Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, “Heart disease is by far the leading killer of Americans. Individuals with different interleukin gene variations have vastly different clinical trajectories for heart disease progression. The ability to know your individual genetic predisposition for this disease is a new and powerful tool to allow a customer and their physicians to design the best preventive care for that person.”

About Coronary Artery Disease

Coronary artery disease (CAD) is an inflammatory disease in which plaque builds up inside the coronary arteries. These arteries supply your heart muscle with oxygen-rich blood. Plaque is made up of fat, cholesterol, and other substances found in the blood. When plaque builds up in the arteries, the condition is called atherosclerosis. Variation in interleukin genes has shown to be associated with different degrees of CAD risk. Over time, CAD can weaken the heart muscle and lead to heart attack and arrhythmias. CAD is the most common type of heart disease and is the leading cause of death in the United States for both men and women. Lifestyle changes, medicines, and/or medical procedures can effectively prevent or treat CAD in most people. Certain cholesterols have also been associated with increased CAD risk. According to the American Heart Association, over 105 million American adults have total blood cholesterol values of 200 mg/dL and higher, and 36.6 million American adults have levels of 240 or above. Doctors consider total cholesterol levels of 240 mg/dL or greater high in adults and levels from 200 to 239 mg/dL borderline-high.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com.

SPEAKING OF AMWAY, how do you  plan to incorporate Gensona and Personalized Health into your Amway Wellness business? Will you be leading with a product opportunity to build a strong, profitable client base from which you will find others who want to build their own part-time businesses? Or will you be leading with a business opportunity and trying to redirect those who are not interested toward products and to become clients?

written by rdknyvr \\ tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Jun 23

According to Interleukin Genetics CEO Lew Bender on ILI’s most recent (Q1) conference call ( http://www.ilgenetics.com/ ) and an outside analyst’s report by Dutton & Associates ( http://www.centredaily.com/business/technology/story/668990.html ), we can expect a relaunch of the Gensona and Personalized Health line by Alticor sometime in Q3 (sometime in the period of July 1 to Sept. 30).

 Interestingly, the domain name AmwayWellness.com was registered by an Alticor-contracted consultant (to the best of my knowledge) as of this past Feb. 29, 2008.

And the new weight loss support market research site from Alticor, sponsored by Nutrilitehttp://community.mybestsize.com/ comes with pointers to a number of interesting features, including ‘personalized health’-related gurus, and suggests a ramp-up to something exciting coming later this year.

So for those interested in building their product knowledge and expertise in nutrigenomics and optimal health, and developing a health-focused Amway-driven business, here are a few relevent resources to check out.

MP3Nutrigenomics, Inflammation and Obesity: A New Paradigm for Personalized Prevention” by Ruth DeBusk, RD, PhD and Colleen Fogarty Draper, MS, RD. MP3 download is $17, CD is $20 plus tax, shipping. Easy to understand for the novice. Ruth DeBusk is on the Nutrilite Science Advisory Board, and Colleen Fogarty Draper, after 6 years with Interleukin Genetics, has recently formed her own consulting/educational company in the area of nutrigenomics. At the link below, see #256 and Product Number 200730131 http://www.intelliquestmedia.com/store/search.php?a=E&c=200730

Courtesy of Colleen Fogarty Draper’s website, the following three downloadable articles provide excellent background reading.

PDFNutritional Genomics in Practice: Where Do We Begin?” http://www.nugenso.com/articles/DeBusk_2005.pdf

PDFEmerging Concepts in Nutrigenomics: A Preview of What Is to Comehttp://www.nugenso.com/articles/Kauwell_2005.pdf

PDFThe Genome Health Clinic and Genome Health Nutrigenomic Concepts” (this article by an Australian researcher is more technical, but will be of interest to IBOs with a health sciences background) http://www.nugenso.com/articles/Fenech_2005.pdf

BOOKSecrets of Supplements: the Good, the Bad, the Totally Terrific” by Gloria Askew, RN and Jerre Paquette, PhD. ISBN: 978-0-9784290-0-3. Gloria is a long-time IBO and has co-authored a very readable, easy to understand book with the beginner in mind. Nowhere does she actually mention the name ‘Nutrilite’ so you can use this book to develop new customers for your Nutrilite product line. The most valuable part of the book is the list of “Ten Totally Terrific Questions” which will guide your prospective client to see that only Nutrilite meets all the key requirements. This book is worth its weight in gold to the Health Business Builder, and for what it’s worth, is being distributed by at least one System (Network 21) in North America and internationally as a key product education resource. 

Free sample chapter and Table of Contents, and online ordering at: http://www.phytemedia.com/  In Canada, Secrets of Suppements can be picked up in store or online at Chapters.

And now for the naughty question… or perhaps more accurately, a knotty question:

In your Quixtar/Amway business, what are you really selling? Are you first and foremost selling a business opportunity, or are you driving a product-based business which has the option of also being duplicated, for those interested in doing so? It’s an important question, and may differentiate between those who are “products of a System” and those who may be operating as non-affiliated “independent” IBOs (if you’ll pardon the redundancy in that).

If the question is unclear, say so and I’ll try to rephrase.

My guess is that if your business is primarily selling a business opportunity, the above resources recommendations were of relatively low relevance to you. If you are focusing on a product-driven business with a strong focus on developing long term clients – and still including networking and duplication — you will make the effort to download and read the documents above, and invest in the Ruth DeBusk MP3 and Gloria Askew’s excellent book on supplements.

SPEAKING OF AMWAY, these are just my thoughts — am I right or wrong?

written by rdknyvr \\ tags: , , , , , , , , , , , , , , , , , , , , , , , ,

May 12
For those interested in staying current on happenings at IL Genetics and Gensona…  THIS WEDNESDAY, MAY 14:
Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results

WALTHAM, MA – May 7, 2008 – Interleukin Genetics, Inc. (AMEX: ILI), announced today that it will host a conference call and webcast on Wednesday, May 14, 2008 at 4:30 p.m. ET [1:30 p.m. Pacific Time Zone] to review the Company’s first quarter 2008 financial results and provide an update on recent corporate developments.
 
To access the live call, dial 877-627-6555 (domestic) or 719-325-4869 (international). The live webcast will be available on the Investors section of the Company’s website, www.ilgenetics.com.

Replay access of the teleconference will be available for one week following the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international). The passcode for the replay is 4243283. The webcast will be archived following the call at www.ilgenetics.com

About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market.

written by rdknyvr \\ tags: , , , , ,

May 01

Interleukin Genetics announced today publication of the results of clinical studies that support the company’s Heart Health Genetic Test to assess cardiovascular risk.  The article, titled, “IL1B Gene Promoter Haplotype Pairs Predict Clinical Levels of Interleukin-1? and C-reactive Protein,” was published in the journal Human Genetics (123:387-398; May 2008) and further confirms prior studies associating variations in the Interleukin 1B (IL1B) gene with the inflammatory response.

The announcement on the PRNewswire adds:  Interleukin Genetics’ Heart Health Genetic Test is available to consumers in the U.S. and Canada under the Gensona® brand and marketed by Alticor Inc. The Gensona® Heart Health Genetic Test employs a number of single nucleotide polymorphisms (genetic sequence variations called SNPs) to identify specific genetic patterns in the Interleukin 1 genes. These genetic patterns are known to correlate with exaggerated inflammatory responses and increased risk of early cardiovascular disease. The Gensona® Heart Health Genetic Test is available in the Personalized Health Products category at Quixtar by e-mail at Quixtar.personalized.health@quixtar.com. Quixtar also can be reached at 800-529-8772.”

To view the entire PRNewswire announcement and to also view a short video by Ken Korman, Chief Scientific Officer of Interleukin Genetics, click here:  http://www.prnewswire.com/mnr/ilgenetics/32863/

written by Chuck Lia \\ tags: , , ,

Mar 24

mocha-at-four-months.jpg

IS GENETIC TESTING GOING TO THE DOGS?

Well, “Yes”………and “No.” 

I own two dogs.  I acquired both through rescue groups and would recommend that avenue to anyone thinking about getting a dog or a cat.

I adopted my second dog “Cocoa,” a female, as a year old youngster in August of 2006 as a companion for my male, “Mocha.”  I was told when I got Cocoa that she was likely a border collie mix.  She has a kind of salt and pepper color, with a full, soft coat, and a face that tells everyone how happy she is 24/7.  She is Miss Personality Plus — a dog with a playful and mischievous side that runs like a gazelle.  She is the Energizer Bunny in a canine costume.  She can go on forever.  

I adopted Mocha as a 7 week old puppy a year earlier in May of 2005.  The picture above is of him at four months.  He has the color and markings of a chestnut thoroughbred with four white stockings, a fluffy white chest, and a long white plume at the end of his tail.  When I first got him I was told his mother was a chocolate lab or Boykin spaniel, but they didn’t know anything about his father.  They said they believed Mocha would grow up to be around 35 to 45 pounds.  Well today (96 pounds later!), I have a very big cuddly boy with the winter coat of a grizzly bear, the demeaner of King Mufasa (you know, from ”The Lion King”), and the heart of a teddy bear.  He’s just Mr. Lovable.  He attracts attention everywhere we go.  No matter where I take him everyone stops us and asks, “What kind of dog is that?  He’s beautiful!”  I always shrug and say, “He really is beautiful, isn’t he?  Sorry to say though, I really don’t know for sure what kind of dog he is.  I wish I did.”  And I really do wish I knew what his genetic heritage is.  And Cocoa’s too.

Fortunately, soon I will. 

High-tech DNA tests are now available that can tell a dog owner what his dog’s genetic heritage is back three generations. These new tests will give owners long baffled by the breed makeup of their mutts something to do besides what I normally do, shrug and speculate.  For $65 MetaMorphix subsidiary, MMI Genomics of Beltsville, Md. can test for about 115 breeds based on the DNA from a cotton swab of your dog’s mouth.  And Mars Veterinary of Virginia offers a blood test through vets which can test for 157 breeds at a cost of $100-$200, depending on your vet.  For me, the days of shrugging will soon be over. 

Interestingly, genetic testing is also rapidly becoming one of the new frontiers in health and wellness.  Alticor is the largest stockholder in Interleukin Genetics, the only company that has developed a DNA based risk assessment test that can tell people whether or not they have a genetic risk factor that affects their own inflammatory response.  Chronic inflammation is now thought to be an important risk factor for heart disease, and interleukin 1 (IL-1) genetic variations have been shown to be an indicator of early cardiac events. 

Interleukin Genetics has been awarded 20 U.S. patents for work linking variations in inflammation genes with risk for disease.  A quick review of Interleukin’s website shows it is at various stages of developmental work on genetics tests for osteoporosis, weight management, general nutrition, cardiovascular disease, skin aging, and PerioNX.  Of importance to Quixtar IBOs is that the Interleukin website states that since 2003 the majority of Interleukin’s development efforts have been part of a broad strategic alliance with Alticor.

Over the past few years Quixtar has been moving toward making itself the leading health and wellness company in North America, and eventually around the world.  It now offers two Interleukin developed genetic tests.  One, the Gensona Heart Health Genetic Test, is the first and only IL1 gene test to identify an individual’s predisposition for over-expression of inflammation and increased risk for cardiovascular disease and acute cardiac events.  The other, the Gensona General Nutrition Genetic Test, identifies nutrient metabolism (including Vitamin B and anti-oxidants).  And then Nutrilite follows behind those tests and offers specific products in response to those tests that can help those found to possess some of the risk markers to maintain and enhance their health.  It can’t get much better than that.  

These kind of product offerings clearly improve Alticor’s and Quixtar’s credibility in the general marketplace, and particularly in the health and wellness field.  Hopefully there will be more offerings to follow in the future from Quixtar as Interleukin’s developmental research moves forward, offerings which obviously would only further enhance Alticor’s and Quixtar’s health and wellness reputations. 

In my opinion, these are the type of products that are integral to the success of the current business transformation, not primarily because of the dollar volume of sales they can generate (even though I know that is very important), but because of what these products reveal about the quality and timeliness of the products Quixtar delivers to the consumer.  How could any reasonable, rational person put products like MonaVie or Xango in the same league with the kind of product offerings coming from Quixtar via Interleukin and Nutrilite today?  Quixtar’s health related products are Major League caliber and truly substantive.  The others are little more than bush league, hype, and spin. 

So is genetic testing going to the dogs?  Thankfully, I can say, “Yes!”  But when it comes to the genetic tests offered by Quixtar, it’s quite clear they are anything but “dogs.”  Quixtar’s genetic tests and Nutrilite’s follow-up products are leading edge and first tier and Quixtar’s IBOs should be excited we can promote and market such terrific product lines.

By the way, when I get the DNA results back I promise I will tell you on this blog what the genetic heritage of my dogs is.  Can’t wait!

What are your thoughts on Quixtar’s latest move into genetic testing? 

written by Chuck Lia \\ tags: , , , , , ,